Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Blood Cancer, Lymphoma, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 10 - 55 |
| Updated: | 4/21/2016 |
| Start Date: | January 2012 |
| End Date: | August 2017 |
| Contact: | Novartis Pharmaceuticals |
| Phone: | 1-888-669-6682 |
A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies
This study is designed to evaluate the safety and tolerability of using HSC835 in patients
with hematological malignancies.
with hematological malignancies.
Inclusion Criteria:
- Patients with a diagnosis that qualifies them for a DUCBT
- Absence of recent active mold infection
- Adequate organ function
- Availability of eligible donor material
Exclusion Criteria:
- Pregnancy or breastfeeding women and women of child-bearing potential unless two
acceptable forms of contraception are being used
- Human immunodeficiency virus (HIV) infection
- Active infection
- Extensive prior chemotherapy
- Prior myeloablative allotransplantation or autologous transplant.
We found this trial at
1
site
Click here to add this to my saved trials
